BELANOFF JOSEPH K sold $895K of CORT (indirect holdings)

BELANOFF JOSEPH K (Chief Executive Officer) sold 12,837 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at $69.74 ($0.90M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BELANOFF JOSEPH K
Published Jun 2, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosure can influence short-term sentiment, but it is not a fundamental catalyst by itself.

02

Market read

Traders may monitor for follow-on insider activity, but this single 10b5-1 sale provides limited new information.

03

What to watch

The filing does not disclose reasons for the sale beyond the plan; without accompanying buys or fundamental updates, directional trading edge is limited.

Relevance 6/10Novelty 3/10Timing: Filed after-hours (2026-06-02) for a sale executed 2026-06-01

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO with a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics CEO Joseph K. Belanoff sold 12,837 shares in an open-market transaction disclosed on Form 4.

Expected impact

Limited, likely sentiment-only drift; no clear directional catalyst from the filing alone.

Evidence & confidence

The filing is an ownership-change disclosure (insider sale) with a stated pre-arranged Rule 10b5-1 plan, reducing the likelihood of immediate fundamental information.

Market effects

Minimal; this is company-specific insider activity without new clinical/regulatory developments.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; price impact may fade quickly.

Key entities

  • CORCEPT THERAPEUTICS INC

    Subject of the Form 4 insider transaction disclosure.

  • BELANOFF JOSEPH K

    CEO and director who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.